EUCTR2010-021179-10-GB进行中（未招募）不适用
An Open Label safety Extension study of olesoxime (TRO19622) in Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole. - OLE safety study of TRO19622 for ALS patients treated with riluzole
TROPHOS0 个研究点目标入组 350 人开始时间: 2011年1月31日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 350
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must have completed the 18-month safety and efficacy study of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole (Protocol TRO19622 CL E Q 1015-1). • Both the investigator and the patient will decide based on previous good tolerance and other clinical grounds whether or not to participate to the open-label extension. • If patients were on anti-vitamin K during the double-blind period, when entering the open-label extension, coagulation tests should be monitored in exactly the same conditions as if a new anticoagulant treatment was initiated and the dose of anti-vitamin K should be adjusted accordingly(see secti on 8.3.11). • Patients enrolling from this prior safety and efficacy study must: – If female of childbearing age of potential, continue to use adequate birth control methods and have a negative serum pregnancy test at the preceding double-blind protocol termination visit. Male and female partners must agree to use an effective method of birth control during their participation in the trial and for at least 15 days after the last IMP dose. Both partners must use reliable methods of contraception with 2 independent methods. The following measures are acceptable: Hormone contraceptives (e.g. oral contraceptives or comparable methods), intrauterine device, condoms with spermicidal coating or in combination with spermicidal creams, total abstinence or sterilisation performed in the past. – Be able to follow the investigator’s instructions and be able to comply with the visit schedule and visit requirements; and – Sign a written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •Patients may not participate to this study if they have an ongoing, unresolved, clinically significant medical problem (including patients having serious adverse events or non-serious, but medically significant adverse events during the preceding safety and efficacy study that was assessed to be related to the study medication by the investigator)that is on the judgment of the investigator would make it unsafe for the patient to participate in the trial.
研究者
相似试验
进行中（未招募）
不适用
An Open Label Safety Extension Study of olesoxime (TRO19622) in Amyotrophic Lateral SclerosisUn extensión del estudio en abierto de la seguridad del TRO19622 en Esclerosis Lateral Amiotrófica (ELA)de los pacientes tratados con riluzol.Amyotrophic Lateral SclerosisEsclerosis Lateral AmiotróficaMedDRA version: 13Level: LLTClassification code 10002026Term: Esclerosis lateral amiotróficaEUCTR2010-021179-10-ESTROPHOS SA
进行中（未招募）
1 期
ong-term safety study of open-label pramipexole extended release(ER) in patients with early Parkinson’s disease (PD).Male or female patients with early idiopathic Parkinson´s disease (PD) with Modified Hoehn and Yahr stage I-III.MedDRA version: 9.1Level: LLTClassification code 10061536Term: Parkinson's diseaseEUCTR2007-004234-16-FRBOEHRINGER INGELHEIM520
进行中（未招募）
1 期
ong-term safety study of open-label pramipexole extended release(ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PDMale or female patients, with idiopathic PD diagnosed for at least 2 years, 30 years of age or older at time of diagnosis, with a modified Hoehn and Yahr scale of 2 to 4 at on-time.MedDRA version: 9.1Level: LLTClassification code 10061536Term: Parkinson's diseaseEUCTR2007-004235-37-SKBoehringer Ingelheim RCV GmbH & Co KG390
进行中（未招募）
1 期
ong-term safety study of open-label pramipexole extended release(ER) in patients with advanced Parkinson’s disease (PD). - Open label extension in advanced PDEUCTR2007-004235-37-HUBoehringer Ingelheim Pharma Ges mbH390
进行中（未招募）
不适用
ong-term safety study of open-label pramipexole extended release(ER) in patients with early Parkinson’s disease (PD).Male or female patients with early idiopathic Parkinson´s disease (PD) with Modified Hoehn and Yahr stage I-III.MedDRA version: 9.1Level: LLTClassification code 10061536Term: Parkinson's diseaseEUCTR2007-004234-16-HUBoehringer Ingelheim Pharma Ges mbH520